FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a method of producing engineered T-cells or natural killer (NK) cells for cellular immunotherapy, engineered T-cell or NK-cell for use in cellular immunotherapy, a population of cells for use in immunotherapy and a pharmaceutical composition for use in treating cancer, where the pharmaceutical composition contains an engineered T-cell or NK-cell or a population of immune cells. In one embodiment, the method comprises the steps of producing a population of primary T cells or NK cells and introducing a nucleic acid into said cells, containing an exogenous polynucleotide sequence coding a chemokine or cytokine to be integrated into an endogenous gene, and one sequence-specific endonuclease reagent.
EFFECT: invention extends the range of products for cellular immunotherapy.
20 cl, 16 dwg, 13 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR IMPROVED IMMUNE CELL THERAPY | 2018 |
|
RU2797304C2 |
| METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | 2013 |
|
RU2663725C2 |
| METHODS FOR CONSTRUCTING ALLOGENIC AND HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2736616C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| METHODS FOR CONSTRUCTING HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2725542C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
